Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: A meta-analysis

BMJ Open

Volumn 5, Issue 4, 2015, Pages

  Hu, Kaimin ^a   Lou, Lixia ^a   Ye, Juan ^a   Zhang, Suzhan ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; HUMAN; KIDNEY CARCINOMA; META ANALYSIS (TOPIC); NEPHRECTOMY; NEUTROPHIL LYMPHOCYTE RATIO; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL NEPHRECTOMY; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; BLOOD; CARCINOMA, RENAL CELL; DISEASE FREE SURVIVAL; KIDNEY NEOPLASMS; LYMPHOCYTE; LYMPHOCYTE COUNT; META ANALYSIS; NEUTROPHIL; PATHOLOGY; PROGNOSIS;

TUMOR MARKER;

BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; HUMANS; KIDNEY NEOPLASMS; LYMPHOCYTE COUNT; LYMPHOCYTES; NEUTROPHILS; PROGNOSIS;

EID: 84929330434     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006404     Document Type: Article

References (40)

1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009;373:1119-32.
2. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010;7:245-57.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
4. MacDonald N. Cancer cachexia and targeting chronic inflammation: a unified approach to cancer treatment and palliative/supportive care. J Support Oncol 2007;5:157-62; discussion 164-156, 183.
5. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
6. Hutterer GC, Stoeckigt C, Stojakovic T, et al. Low preoperative lymphocyte-monocyte ratio (LMR) represents a potentially poor prognostic factor in nonmetastatic clear cell renal cell carcinoma. Urol Oncol 2014;32:1041-8.
7. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010;6:149-63.
8. Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011;47:2633-41.
9. Pichler M, Hutterer GC, Stojakovic T, et al. High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients. Br J Cancer 2013;109:1123-9.
10. Li MX, Liu XM, Zhang XF, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer 2014;134:2403-13.
11. Xiao WK, Chen D, Li SQ, et al. Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis. BMC Cancer 2014;14:117-26.
12. Ohno Y, Nakashima J, Ohori M, et al. Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit from cytoreductive nephrectomy: neutrophil-to-lymphocyte ratio and performance status. Int J Clin Oncol 2014;19:139-45.
13. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007;28:105-14.
14. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
15. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455-63.
16. De Martino M, Pantuck AJ, Hofbauer S, et al. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urol 2013;190:1999-2004.
17. Ohno Y, Nakashima J, Ohori M, et al. Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. J Urol 2012;187:411-17.
18. Dirican A, Kucukzeybek Y, Erten C, et al. Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. Asian Pac J Cancer Prev 2013;14:2101-5.
19. Keizman D, Gottfried M, Ish-Shalom M, et al. Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib. Oncologist 2014;19:51-60.
20. Santoni M, De Giorgi U, Iacovelli R, et al. Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. Br J Cancer 2013;109:1755-9.
21. Cetin B, Berk V, Kaplan MA, et al. Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma? Clin Genitourin Cancer 2013;11:141-8.
22. Forget P, Machiels JP, Coulie PG, et al. Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol 2013;20(Suppl 3):S650-60.
23. Pichler M, Hutterer GC, Stoeckigt C, et al. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer 2013;108:901-7.
24. Kobayashi M, Kubo T, Komatsu K, et al. Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy. Med Oncol 2013;30:556.
25. Templeton AJ, Heng DYC, Choueiri TK, et al. Neutrophil to lymphocyte ratio (NLR) and its effect on the prognostic value of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model for patients treated with targeted therapy (TT). J Clin Oncol 2014;32.
26. Fox P, Hudson M, Brown C, et al. Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. Br J Cancer 2013;109:147-53.
27. Huang P, Carducci MA, Eisenberger MA, et al. The association of pretreatment (pre-tx) neutrophil to lymphocyte ratio (NLR) with outcome of sunitinib tx in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2011;29(15 Suppl):4621.
28. Hatakeyama S, Yoneyama T, Hamano I, et al. Prognostic benefit of surgical management in renal cell carcinoma patients with thrombus extending to the renal vein and inferior vena cava: 17-year experience at a single center. BMC Urol 2013;13:47.
29. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326:219.
30. Jagdev SP, Gregory W, Vasudev NS, et al. Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein. Br J Cancer 2010;103:1649-56.
31. Lamb GW, Aitchison M, Ramsey S, et al. Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems. Br J Cancer 2012;106:279-83.
32. Tai CG, Johnson TV, Abbasi A, et al. External validation of the modified Glasgow prognostic score for renal cancer. Indian J Urol 2014;30:33-7.
33. de Martino M, Haitel A, Schatzl G, et al. The protease activated receptor 1 gene variation IVSn -14 A>T is associated with distant metastasis and cancer specific survival in renal cell carcinoma. J Urol 2013;190:1392-7.
34. Vilella-Arias SA, Rocha RM, da Costa WH, et al. Loss of caspase 7 expression is associated with poor prognosis in renal cell carcinoma clear cell subtype. Urology 2013;82:974.e1-7.
35. Shi X, Jiang J, Ye X, et al. Prognostic prediction and diagnostic role of intercellular adhesion molecule-1 (ICAM1) expression in clear cell renal cell carcinoma. J Mol Histol 2014;45:427-34.
36. Diamond E, Riches J, Faltas B, et al. Immunologics and chemotherapeutics for renal cell carcinoma. Semin Intervent Radiol 2014;31:91-7.
37. Gerber HP, Olazoglu E, Grewal IS. Targeting inflammatory cells to improve anti-VEGF therapies in oncology. Recent Results Cancer Res 2010;180:185-200.
38. Santoni M, Massari F, Amantini C, et al. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 2013;62:1757-68.
39. Mano Y, Shirabe K, Yamashita Y, et al. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg 2013;258:301-5.
40. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565-70.